GUANGZHOU, China, Oct. 12 /Xinhua-PRNewswire-FirstCall/ -- China Medicine Corporation ("CMC") (OTC Bulletin Board: CHME), a leading distributor of prescription and over the counter pharmaceutical products, traditional Chinese medicines (finished medicines made of Chinese herbs), Chinese herbs, nutritional supplements, dietary supplements, medical supplies and medical formulations today announced the Company's ADTZ (Aflatoxin-detoxifizyme) project has been selected by Guangdong Province as one of six patent commercialization projects.
These selected six projects will receive financial and other support from the provincial and local government in order to assist in the rapid commercialization of the technologies.
Mr. Shenshan Yang, CEO of China Medicine stated, "Our ADTZ project has made tremendous progress and we believe that the financial and political support of the government will expedite commercialization of the product. We look forward to working closely with the government and a successful product launch."
About China Medicine Corporation
China Medicine is a distributor of medical products, traditional pharmaceutical medicines, traditional Chinese medicines, Chinese herbs and dietary supplements to over 28 provinces and 2,500 customers within China. The Company sells more than 1,100 products and is actively building a pipeline of proprietary traditional and Chinese herbal remedy products targeting oncology, high blood pressure and the removal of Aflatoxins from food and animal feed. For more information visit the Company's website at http://www.chinamedicinecorp.com .
Safe Harbor Statement
This press release contains forward-looking statements concerning China
Medicine Corporation's business and products. The actual results may differ
materially depending on a number of risk factors including, but not limited
to, the following: general economic and business
'/>"/>
| SOURCE China Medicine Corporation Copyright©2007 PR Newswire. All rights reserved |